Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Affitech signs SCA license deal
April 2007
SHARING OPTIONS:

OSLO, NorwayŚAffitech AS, a privately held Norwegian biotechnology company focused on the discovery and development of therapeutic human monoclonal antibodies, announced that it has signed an agreement with Micromet AG for a non-exclusive worldwide sub-licenseable research license to the joint patent estate of Micromet and Enzon Pharmaceuticals, Inc. in the field of single-chain antibodies (SCA).
 
Under the terms of the agreement, Affitech will have rights to conduct research involving SCA technology and will have sublicense rights to third parties for the purpose to conduct research, develop or use an SCA product generated by Affitech. No other terms of the agreement were announced.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.